SOURCE: Cerecor Inc

Cerecor Inc

February 03, 2012 09:30 ET

Cerecor Announces Scientific Advisory Board

BALTIMORE, MD--(Marketwire - Feb 3, 2012) - Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced the members of its Scientific Advisory Board, established to supplement its management team.

"We believe that now is an opportune time in the company's life to announce this world-class board of strategic, scientific advisors on whom we routinely call for advice," stated Blake M Paterson, M.D., Co-founder & CEO of Cerecor. "We welcome this distinguished group of highly accomplished professionals to the Cerecor team and believe they will provide inestimable value to the company as we continue to make progress in the coming months and years." Dr. Solomon H. Snyder, Chair of the Scientific Advisory Board, commented, "Historically, carefully selected scientists of diverse and broad backgrounds, working coordinately in advisory groups, have substantially enhanced innovation in the biopharmaceutical industry."

Scientific Advisory Board

The Scientific Advisory Board of the company is chaired by Solomon H. Snyder, MD, discoverer of the opiate receptor and Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry at Johns Hopkins University School of Medicine, is the recipient of numerous professional awards including the Albert Lasker Award for Basic Biomedical Research and the National Medal of Science. Other members of the board include Ronald Borchardt, PhD, a pioneer in the field of drug delivery and Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry at The University of Kansas; Steven Paul, MD, Director of the Helen and Robert Appel Alzheimer's Disease Research Institute and Professor of Neurology and Psychiatry at Weill Cornell Medical College, formerly the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories of Eli Lilly and Company; Dennis Liotta, PhD, inventor of emtricitabine, the most used anti-HIV drug and a Professor of Organic Chemistry, Department of Chemistry, Emory University; Anne Young, MD, Chief, Neurology Service; Director, MassGeneral Institute for Neurodegenerative Diseases; and Barbara Slusher, PhD, Chief Scientific Officer, Brain Science Institute NeuroTranslational Program, JHU.

About Cerecor, Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"). Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset. www.cerecor.com

Contact Information

  • For More Information:
    Jeff Ramson
    ProActive Capital Resources Group
    (646) 863-6341